Please login to the form below

Not currently logged in
Email:
Password:

BMS/Roche deal for skin cancer drug

Bristol-Myers Squibb and Roche have entered into an agreement to research the combination of ipilimumab and vemurafenib for metastatic melanoma

Bristol-Myers Squibb (BMS) and Roche have entered into an agreement to research the combination of two drugs for the treatment of metastatic melanoma.

Under the agreement, the two companies will conduct a phase I/II study to evaluate the safety and efficacy of the combination of BMS' CTLA-4 inhibitor Yervoy (ipilimumab) and Roche's investigational oral BRAF inhibitor, vemurafenib.

Yervoy was recently approved by the US Food and Drug Adminstration (FDA) for the treatment of unresectable or metastatic melanoma.

If the initial trials are successful, the companies will conduct further development of the combination.

Both drugs have shown individual positive results in recent studies. A second phase III trial of Yervoy published in the New England Journal of Medicine showed significant improvement in overall survival for patients with metastatic melanoma who took Yervoy in combination with the chemotherapy dacarbazine compared to dacarbazine alone.

Roche also recently announced the results of a phase III trial that showed vemurafenib improved overall survival in people with a form of metastatic melanoma when compared to chemotherapy.

"We are excited to be working with Roche to evaluate the potential that together Yervoy and vemurafenib could improve outcomes for melanoma patients," said Brian Daniels, senior vice president, development and medical affairs, BMS.

6th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics